And this update only applies to people with IDH1/2 mutant glioma. Perhaps ... But I think some will be asking what the clinical activity of vorasidenib is in that setting. There are some suggestions ...

Published recently in the journal Frontiers in Nutrition, the report is the first evaluation of the use of ketogenic metabolic therapy (KMT) without chemo or radiation interventions, on a patient ...

With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses an unmet need in personalized cancer treatment, offering new hope for patients with limited options. As clinical ...